Tapentadol is a centrally-acting analgesic with a dual mechanism that makes it distinct from tramadol. Its mechanism includes:

• A Mu-opioid receptor agonism and norepinephrine reuptake inhibition (MOR-NRI), without significant serotonin reuptake inhibition ✓
• B Mu-opioid receptor agonism and selective serotonin reuptake inhibition
• C Kappa-opioid receptor agonism and delta-opioid receptor antagonism
• D NMDA receptor antagonism and opioid receptor agonism

Explanation

Tapentadol acts via mu-opioid receptor agonism combined with norepinephrine reuptake inhibition (MOR-NRI). Unlike tramadol (which inhibits both serotonin and norepinephrine reuptake and depends on CYP2D6 conversion for opioid effect), tapentadol has minimal serotonin reuptake inhibition and does not rely on metabolic activation. This reduces serotonin-related adverse effects (nausea, serotonin syndrome risk) and eliminates the pharmacogenomic variability associated with CYP2D6 status. Norepinephrine reuptake inhibition activates descending inhibitory pain pathways, particularly useful for neuropathic pain.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.